Article Text

Download PDFPDF

Low dose aspirin lowered stroke risk but not risks of MI or cardiovascular deaths in women

Statistics from

 Q Is low dose aspirin effective for the primary prevention of cardiovascular disease in women?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Neurology ★★★★★★☆ Haematology ★★★★★★☆


Embedded ImageDesign:

randomised, placebo controlled trial (Women’s Health Study).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded {healthcare providers, participants, data collectors, and outcome assessors}.*

Embedded ImageFollow up period:

mean 10 years.

Embedded ImageSetting:

USA and Puerto Rico.

Embedded ImageParticipants:

39 876 women ⩾45 years of age (mean age 55 y) who had no history of coronary artery disease, cerebrovascular disease, cancer (except non-melanoma skin cancer), or other major chronic illness; contraindication to the study medications; were not taking aspirin, non-steroidal anti-inflammatory drugs, anticoagulants, or corticosteroids; and were not taking vitamin A or E, or ß carotene supplements more than once per week.

Embedded ImageIntervention:

aspirin, 100 mg every other day (n = 19 934) or placebo (n = 19 942).

Embedded ImageOutcomes:

first major cardiovascular event (non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death); individual cardiovascular endpoints; and adverse events.

Embedded ImagePatient follow up:

97% (intention to treat analysis).


The table shows …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd